Elevated Levels of Soluble CD14 in Serum of Patients with Systemic Lupus Erythematosus

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1994 Apr 1

PMID 7512005

Citations 39

Authors

W A Nockher

R Wigand

W SCHOEPPE

J E Scherberich

Affiliations

Soon will be listed here.

Abstract

A soluble form of CD14 (sCD14) was assessed with an ELISA assay in the serum of the following three clinical groups: 35 patients with an inactive phase of systemic lupus erythematosus (SLE), 17 patients with SLE relapses, and 65 normal healthy volunteers. Increased levels of sCD14 were observed in all patients suffering from SLE compared with normal controls. In addition, patients with active SLE revealed higher serum concentrations of sCD14 (median 6.9 mg/l) than patients under remission (4.1 mg/l; P < 0.0001). Serum values of sCD14 correlated neither with the number of peripheral blood monocytes bearing the CD14 membrane antigen, nor with serum concentrations of IL-1 beta. Serum sCD14 was compared with other clinical parameters used to monitor the clinical course of patients with SLE, among them complement C3, anti-dsDNA antibodies and soluble IL-2 receptor (sIL-2R). A good correlation emerged between sCD14 and C3 as well as sIL-2R concentrations, but sCD14 and anti-dsDNA titres disclosed no significant correlation in both groups of patients with SLE. Serial studies in patients with severe SLE showed that serum sCD14 closely parallels the clinical course as defined by an activity score. Our data suggest that serum sCD14 represents a promising parameter to monitor disease activity in patients with SLE.

Citing Articles

SLE serum induces altered goblet cell differentiation and leakiness in human intestinal organoids.

Hensel I, Elias S, Steinhauer M, Stoll B, Benfatto S, Merkt W EMBO Mol Med. 2024; 16(3):547-574.

PMID: 38316934 PMC: 10940301. DOI: 10.1038/s44321-024-00023-3.

Immune Responses at Host Barriers and Their Importance in Systemic Autoimmune Diseases.

Schinnerling K, Penny H, Soto J, Melo-Gonzalez F Adv Exp Med Biol. 2023; 1408:3-24.

PMID: 37093419 DOI: 10.1007/978-3-031-26163-3_1.

Smartphone-Based Quantitative Analysis of Protein Array Signals for Biomarker Detection in Lupus.

Yang G, Li Y, Tang C, Lin F, Wu T, Bao J Chemosensors (Basel). 2022; 10(8).

PMID: 36072130 PMC: 9447405. DOI: 10.3390/chemosensors10080330.

Amyloid-containing biofilms and autoimmunity.

Miller A, de Anda J, Wong G, Tukel C Curr Opin Struct Biol. 2022; 75:102435.

PMID: 35863164 PMC: 9847210. DOI: 10.1016/j.sbi.2022.102435.

Loss of Gut Barrier Integrity In Lupus.

Ma L, Morel L Front Immunol. 2022; 13:919792.

PMID: 35795671 PMC: 9250981. DOI: 10.3389/fimmu.2022.919792.

References

Shirakawa F, Yamashita U, Suzuki H . Decrease in HLA-DR-positive monocytes in patients with systemic lupus erythematosus (SLE). J Immunol. 1985; 134(6):3560-2. View

Phillips R, Lomnitzer R, Wadee A, Rabson A . Defective monocyte function in patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 1985; 34(1):69-76. DOI: 10.1016/0090-1229(85)90008-x. View

Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger J, Kostka W . Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur J Immunol. 1986; 16(12):1583-9. DOI: 10.1002/eji.1830161218. View

Isenberg D, Dudeney C, Williams W, Addison I, Charles S, Clarke J . Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis. 1987; 46(6):448-56. PMC: 1002163. DOI: 10.1136/ard.46.6.448. View

Goyert S, Ferrero E, Rettig W, Yenamandra A, Obata F, Le Beau M . The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. Science. 1988; 239(4839):497-500. DOI: 10.1126/science.2448876. View

Stuart P, Zlotnik A, Woodward J . Induction of class I and class II MHC antigen expression on murine bone marrow-derived macrophages by IL-4 (B cell stimulatory factor 1). J Immunol. 1988; 140(5):1542-7. View

Ferrero E, Goyert S . Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14. Nucleic Acids Res. 1988; 16(9):4173. PMC: 336598. DOI: 10.1093/nar/16.9.4173. View

Wolf R, Brelsford W . Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988; 31(6):729-35. DOI: 10.1002/art.1780310605. View

Haziot A, Chen S, Ferrero E, Low M, Silber R, Goyert S . The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol. 1988; 141(2):547-52. View

10.

Huang Y, Perrin L, MIESCHER P, Zubler R . Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol. 1988; 141(3):827-33. View

11.

Andreesen R, Gadd S, Brugger W, LOHR G, Atkins R . Activation of human monocyte-derived macrophages cultured on Teflon: response to interferon-gamma during terminal maturation in vitro. Immunobiology. 1988; 177(2):186-98. DOI: 10.1016/s0171-2985(88)80038-x. View

12.

Inghirami G, Simon J, Balow J, Tsokos G . Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol. 1988; 6(3):269-76. View

13.

Simmons D, Tan S, Tenen D, Nicholson-Weller A, Seed B . Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood. 1989; 73(1):284-9. View

14.

Setoguchi M, NASU N, Yoshida S, Higuchi Y, Akizuki S, Yamamoto S . Mouse and human CD14 (myeloid cell-specific leucine-rich glycoprotein) primary structure deduced from cDNA clones. Biochim Biophys Acta. 1989; 1008(2):213-22. DOI: 10.1016/0167-4781(80)90012-3. View

15.

ter Borg E, Horst G, Hummel E, Limburg P, Kallenberg C . Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990; 33(5):634-43. DOI: 10.1002/art.1780330505. View

16.

Wright S, Ramos R, Tobias P, Ulevitch R, Mathison J . CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990; 249(4975):1431-3. DOI: 10.1126/science.1698311. View

17.

ter Borg E, Horst G, Limburg P, Kallenberg C . Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol. 1990; 82(1):21-6. PMC: 1535173. DOI: 10.1111/j.1365-2249.1990.tb05398.x. View

18.

Lauener R, Goyert S, Geha R, Vercelli D . Interleukin 4 down-regulates the expression of CD14 in normal human monocytes. Eur J Immunol. 1990; 20(11):2375-81. DOI: 10.1002/eji.1830201103. View

19.

Stekman I, Blasini A, Leon-Ponte M, Baroja M, Abadi I, Rodriguez M . Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus. Arthritis Rheum. 1991; 34(4):459-67. DOI: 10.1002/art.1780340411. View

20.

Ward M, Dooley M, Christenson V, Pisetsky D . The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus. J Rheumatol. 1991; 18(2):235-40. View